Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

Prosensa begins FDA submission process for DMD drug

Authored by James Sheppard The Dutch biotechnology company Prosensa has announced that it has begun the submission process for its Duchenne Muscular Dystrophy (DMD) drug Drisapersen with the FDA. Prosensa has hoped that it will fully file by the year … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , | Leave a comment

Rare Disease Biotech Summit plc Appoints Erik Ostrowski as CFO

Authored by James Sheppard The Oxford Biotech cluster based rare disease biotech Summit plc has announced the appointment of a new Chief Financial Officer (CFO). Summit announced that Mr Erik Ostrowski will join the company as CFO with immediate effect … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business, Recruitment Market | Tagged , , , , , , , , , , , , | Leave a comment

Wilson Therapeutics Raises $40m to advance development program

Authored by James Sheppard The Stockholm based rare disease biotech, Wilson Therapeutics, announced that it had raises $40m in series B funding. The funding was co-led by new investors Abingworth LLP and MVM Life Science Partners LLP. The new investors … Continue reading

Posted in Executive Appointments, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Kite Pharma expands senior management and board

Authored by James Sheppard The California based biotech Kite Pharma has appointed the former chief financial officer of Amgen, Mr Jonathan M. Peacock, to its board of directors. Kite Pharma is focused on developing engineered autologous T Cell Therapy (eACT). … Continue reading

Posted in Orphan Drugs and Rare Diseases, Recruitment Market | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

New Enterprise Associates backs veteran rare diseases executive team

Authored by Karl Simpson New Enterprise Associates (NEA) has been showing its increasing appetite for rare disease investments as it puts it recent fund to work. With money already invested in companies like Cydan Corporation (led by Cristina Csimma), KLS … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , | Leave a comment

Dr Francois Nader – NPS Pharmaceuticals – Executive Leadership Series

Authored by Karl Simpson At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr Francois Nader performed for NPS Pharmaceuticals in 2013. 2013 Liftstream … Continue reading

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , | Leave a comment

Dr John Martin – Gilead – Executive Leadership Series

Authored by James Sheppard At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Dr John Martin performed for Gilead in 2013. 2013 Liftstream Analysis: Gilead Sciences … Continue reading

Posted in Pharmaceutical business | Tagged , , , , , , , , , , , , , , , | Leave a comment

Jazz Pharmaceuticals to acquire rare disease company Gentium

Authored by James Sheppard Jazz Pharmaceuticals, based in Dublin, Ireland, recently announced that it had acquired Italian based rare disease drug company Gentium in a $1bn deal. The deal will give Jazz access to Gentium’s 3 marketed products and extensive … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , | 2 Comments

Billionaires send Ganymed racing through clinic

Authored by James Sheppard The Germany biotechnology company Ganymed has announced that it had successfully raised $60m in a new venture round to advance the ongoing phase IIa and phase IIb study of IMAB362 for gastroesophageal cancer. Ganymed has now … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

Swedish Pharmalink receives Orphan Drug Approval for Busulipo

Authored by James Sheppard The Swedish speciality pharmaceutical company Pharmalink AB announced that it had received Orphan Drug approval from the US FDA for oncology conditioning agent Busulipo. Busulipo is indicated for use in cancer patients prior to hematopoietic stem … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap